Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioLineRx (BLRX) Operating Margin: 2023-2025

Historic Operating Margin for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to -757.57%.

  • BioLineRx's Operating Margin fell 65052.00% to -757.57% in Q2 2025 from the same period last year, while for Jun 2025 it was -84.09%, marking a year-over-year increase of 25753.00%. This contributed to the annual value of -70.52% for FY2024, which is 96477.00% up from last year.
  • According to the latest figures from Q2 2025, BioLineRx's Operating Margin is -757.57%, which was up 19.21% from -937.65% recorded in Q1 2025.
  • BioLineRx's 5-year Operating Margin high stood at 1,992.06% for Q4 2023, and its period low was -1,476.34% during Q3 2023.
  • Its 3-year average for Operating Margin is -320.05%, with a median of -425.28% in 2023.
  • Within the past 5 years, the most significant YoY rise in BioLineRx's Operating Margin was 136,736bps (2024), while the steepest drop was 202,973bps (2024).
  • BioLineRx's Operating Margin (Quarterly) stood at 1,992.06% in 2023, then crashed by 202,973bps to -37.67% in 2024, then tumbled by 65,052bps to -757.57% in 2025.
  • Its Operating Margin was -757.57% in Q2 2025, compared to -937.65% in Q1 2025 and -37.67% in Q4 2024.